Unknown

Dataset Information

0

Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.


ABSTRACT: BACKGROUND:In the United States, there is well-documented regional variation in prescription drug spending. However, the specific role of physician adoption of brand name drugs on the variation in patient-level prescription drug spending is still being investigated across a multitude of drug classes. Our study aims to add to the literature by determining the association between physician adoption of a first-in-class anti-diabetic (AD) drug, sitagliptin, and AD drug spending in the Medicare and Medicaid populations in Pennsylvania. METHODS:We obtained physician-level data from QuintilesIMS Xponent™ database for Pennsylvania and constructed county-level measures of time to adoption and share of physicians adopting sitagliptin in its first year post-introduction. We additionally measured total AD drug spending for all Medicare fee-for-service and Part D enrollees (N?=?125,264) and all Medicaid (N?=?50,836) enrollees with type II diabetes in Pennsylvania for 2011. Finite mixture model regression, adjusting for patient socio-demographic/clinical characteristics, was used to examine the association between physician adoption of sitagliptin and AD drug spending. RESULTS:Physician adoption of sitagliptin varied from 44 to 99% across the state's 67 counties. Average per capita AD spending was $1340 (SD $1764) in Medicare and $1291 (SD $1881) in Medicaid. A 10% increase in the share of physicians adopting sitagliptin in a county was associated with a 3.5% (95% CI: 2.0-4.9) and 5.3% (95% CI: 0.3-10.3) increase in drug spending for the Medicare and Medicaid populations, respectively. CONCLUSIONS:In a medication market with many choices, county-level adoption of sitagliptin was positively associated with AD spending in Medicare and Medicaid, two programs with different approaches to formulary management.

SUBMITTER: Metes ID 

PROVIDER: S-EPMC6794771 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.

Metes Ilinca D ID   Xue Lingshu L   Chang Chung-Chou H CH   Huskamp Haiden A HA   Gellad Walid F WF   Lo-Ciganic Wei-Hsuan WH   Choudhry Niteesh K NK   Richards-Shubik Seth S   Guclu Hasan H   Donohue Julie M JM  

BMC health services research 20191016 1


<h4>Background</h4>In the United States, there is well-documented regional variation in prescription drug spending. However, the specific role of physician adoption of brand name drugs on the variation in patient-level prescription drug spending is still being investigated across a multitude of drug classes. Our study aims to add to the literature by determining the association between physician adoption of a first-in-class anti-diabetic (AD) drug, sitagliptin, and AD drug spending in the Medica  ...[more]

Similar Datasets

| S-EPMC3682054 | biostudies-literature
| S-EPMC3484377 | biostudies-literature
| S-EPMC5338209 | biostudies-literature
| S-EPMC3130847 | biostudies-literature
| S-EPMC6153168 | biostudies-literature
| S-EPMC6417956 | biostudies-literature
| S-EPMC6994362 | biostudies-literature
| S-EPMC9585123 | biostudies-literature
| S-EPMC9579917 | biostudies-literature
| S-EPMC3285245 | biostudies-literature